BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Saab S, Rheem J, Sundaram V. Hepatitis C Infection in the Elderly. Dig Dis Sci. 2015;60:3170-3180. [PMID: 26008618 DOI: 10.1007/s10620-015-3717-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Suraweera D, Jimenez M, Viramontes M, Jamal N, Grotts J, Elashoff D, Lee EW, Saab S. Age-related Morbidity and Mortality After Transjugular Intrahepatic Portosystemic Shunts. Journal of Clinical Gastroenterology 2017;51:360-3. [DOI: 10.1097/mcg.0000000000000541] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
2 Durazzo M, Ponzo E, Bonetto S, Fagoonee S, Pellicano R. Liver diseases in the elderly. Minerva Med 2019;110. [DOI: 10.23736/s0026-4806.18.05858-5] [Cited by in Crossref: 8] [Article Influence: 2.7] [Reference Citation Analysis]
3 Hui YT, Wong GLH, Fung JYY, Chan HLY, Leung NWY, Liu SD, Liu K, Ma YK, But DYK, Mak WY, Chan JMC, Lai KB, Loo CK, Ng ACY, Lai MS, Chan CW, Lau JYL, Fan TTT, Hui AJ, Lam BCY, Cheung WI, Tsang OTY, Lam K, Lai LSW, Luk WF, Li MKK, Lao WC, Lam JTW, Tsang SWC, Kung KN, Chow WH, Tong RKN, Lui TKL, Shan EHS, Yuen MF, Wong VWS. Territory-wide population-based study of chronic hepatitis C infection and implications for hepatitis elimination in Hong Kong. Liver Int 2018;38:1911-9. [PMID: 29981176 DOI: 10.1111/liv.13926] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
4 González-Colominas E, Batlle M, Monge-Escartín I, Duran X, Viu A, de Antonio-Cuscó M, Grau S, Bessa X, Carrión JA. Impact of HCV cure with drug-acting antivirals in the use of concomitant medication and lipid profile: follow-up data 2 years after the sustained virological response. Eur J Gastroenterol Hepatol 2021;32:214-22. [PMID: 32195695 DOI: 10.1097/MEG.0000000000001714] [Reference Citation Analysis]
5 Conti F, Brillanti S, Buonfiglioli F, Vukotic R, Morelli MC, Lalanne C, Massari M, Foschi FG, Bernabucci V, Serio I, Prati GM, Negri E, Badia L, Caraceni P, Muratori P, Vitale G, Porro A, Morotti M, Mazzella G, Andreone P. Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older. J Viral Hepat. 2017;24:454-463. [PMID: 27976461 DOI: 10.1111/jvh.12663] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 7.2] [Reference Citation Analysis]
6 Kinoshita A, Koike K, Mizuno Y, Ogata I, Kobayashi Y, Hasegawa K, Shiraishi K, Yoshida H, Nakata R, Yamada N, Yasuda K. Efficacy and safety of glecaprevir/pibrentasvir in patients with hepatitis C virus infection aged ≥75 years. Geriatr Gerontol Int 2020;20:578-83. [PMID: 32267087 DOI: 10.1111/ggi.13919] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Lens S, Fernández I, Rodríguez-Tajes S, Hontangas V, Vergara M, Forné M, Calleja JL, Diago M, Llaneras J, Llerena S, Torras X, Sacristán B, Roget M, Fernández-Rodríguez CM, Navascués MC, Fuentes J, Sánchez-Ruano JJ, Simón MÁ, Sáez-Royuela F, Baliellas C, Morillas R, Forns X; Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collaborating Group. Interferon-Free Therapy in Elderly Patients With Advanced Liver Disease. Am J Gastroenterol 2017;112:1400-9. [PMID: 28585554 DOI: 10.1038/ajg.2017.157] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
8 Pugliese N, Giorgini A, Maggi D, Capogreco A, Dibenedetto C, Lubrano Lobianco F, Dal Buono A, Monico S, Meli R, Battezzati PM, Lleo A, De Santis A, Zuin M, Aghemo A. Directly acting antivirals are safe and effective in HCV positive patients aged 80 years and older: a multicenter real-life study. Expert Opin Drug Saf 2021;20:839-43. [PMID: 33881366 DOI: 10.1080/14740338.2021.1921144] [Reference Citation Analysis]
9 Suraweera D, Weeratunga AN, Saab S. Spotlight on grazoprevir-elbasvir once-daily combination and its potential in the treatment of hepatitis C. Drug Des Devel Ther 2016;10:2119-27. [PMID: 27418810 DOI: 10.2147/DDDT.S90537] [Cited by in Crossref: 6] [Article Influence: 1.0] [Reference Citation Analysis]
10 Naganuma A, Chayama K, Notsumata K, Gane E, Foster GR, Wyles D, Kwo P, Crown E, Bhagat A, Mensa FJ, Otani T, Larsen L, Burroughs M, Kumada H. Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection. J Gastroenterol 2019;54:752-61. [PMID: 30868245 DOI: 10.1007/s00535-019-01569-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
11 Kamel S, Elessawy H, Ashraf O, Elbaz A, Dabbous H, El-sayed M, Ali S, Kamel H. Effectiveness of Direct-Acting Antivirals in Treatment of Elderly Egyptian Chronic Hepatitis C Patients. Gastroenterology Insights 2021;12:336-46. [DOI: 10.3390/gastroent12030031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Vo Quang E, Shimakawa Y, Nahon P. Epidemiological projections of viral-induced hepatocellular carcinoma in the perspective of WHO global hepatitis elimination. Liver Int 2021;41:915-27. [PMID: 33641230 DOI: 10.1111/liv.14843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Pan CQ, Gayam V, Rabinovich C, Normatov M, Fidman B, Wang D, Garlapati P. Efficacy of Direct-Acting Antivirals for Chronic Hepatitis C in a Large Cohort of Older Adults in the United States. J Am Geriatr Soc 2020;68:379-87. [PMID: 31647119 DOI: 10.1111/jgs.16206] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
14 Amoros-Reboredo P, Soy D, Hernandez-Hernandez M, Lens S, Mestres C. Anticholinergic Burden and Safety Outcomes in Older Patients with Chronic Hepatitis C: A Retrospective Cohort Study. Int J Environ Res Public Health 2020;17:E3776. [PMID: 32466526 DOI: 10.3390/ijerph17113776] [Reference Citation Analysis]
15 Ozono Y, Nagata K, Hasuike S, Iwakiri H, Nakamura K, Tsuchimochi M, Yamada Y, Takaishi Y, Sueta M, Miike T, Tahara Y, Yamamoto S, Shide K, Hidaka T, Kubuki Y, Kusumoto K, Ochiai T, Kato J, Komada N, Hirono S, Kuroki K, Shigehira M, Shimoda K. Efficacy and safety of sofosbuvir and ledipasvir in Japanese patients aged 75 years or over with hepatitis C genotype 1. World J Hepatol 2017; 9(36): 1340-1345 [PMID: 29359017 DOI: 10.4254/wjh.v9.i36.1340] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
16 Foster GR, Asselah T, Kopecky-Bromberg S, Lei Y, Asatryan A, Trinh R, Zadeikis N, Mensa FJ. Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older. PLoS One. 2019;14:e0208506. [PMID: 30601818 DOI: 10.1371/journal.pone.0208506] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
17 Stasi C, Silvestri C, Voller F. Update on Hepatitis C Epidemiology: Unaware and Untreated Infected Population Could Be the Key to Elimination. SN Compr Clin Med. 2020;1-8. [PMID: 33103061 DOI: 10.1007/s42399-020-00588-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
18 Lu M, Li J, Rupp LB, Zhou Y, Holmberg SD, Moorman AC, Spradling PR, Teshale EH, Boscarino JA, Daida YG, Schmidt MA, Trudeau S, Gordon SC. Changing trends in complications of chronic hepatitis C. Liver Int 2018;38:239-47. [PMID: 28636782 DOI: 10.1111/liv.13501] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
19 De Santis A, Maggi D, Lubrano Lobianco F. Safety and efficacy of directly‐acting antiviral therapy for chronic hepatitis C virus in elderly people. Aging Medicine 2021;4:304-16. [DOI: 10.1002/agm2.12190] [Reference Citation Analysis]
20 Amoros-Reboredo P, Sotoca JM, Mariño Z, Rodríguez-Tajes S, Pocurull A, Soy D, Forns X, Lens S. Efficacy and safety of direct-acting antivirals in older patients with cirrhosis and high comorbidity index. Eur J Gastroenterol Hepatol 2020;32:389-94. [PMID: 31441796 DOI: 10.1097/MEG.0000000000001518] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Mikulic D, Mrzljak A. Liver transplantation and aging. World J Transplant 2020; 10(9): 256-266 [PMID: 32995320 DOI: 10.5500/wjt.v10.i9.256] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
22 Saab S, Park SH, Mizokami M, Omata M, Mangia A, Eggleton E, Zhu Y, Knox SJ, Pang P, Subramanian M, Kowdley K, Afdhal NH. Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. Hepatology 2016;63:1112-9. [PMID: 26704693 DOI: 10.1002/hep.28425] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 9.7] [Reference Citation Analysis]
23 Lee SH, Jin YJ, Shin JY, Lee JW. Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs. Medicine (Baltimore). 2017;96:e5321. [PMID: 28072684 DOI: 10.1097/md.0000000000005321] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]